Abeona Therapeutics(US:ABEO) Globenewswire·2025-10-30 14:45Core Insights - Abeona Therapeutics has received a permanent HCPCS J-code for its gene therapy ZEVASKYN, which will enhance reimbursement processes and patient access starting January 1, 2026 [1][2] Company Overview - Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases [7] - ZEVASKYN (prademagene zamikeracel) is the first and only autologous cell sheet-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB) [3][4] Product Details - ZEVASKYN is designed to treat wounds in adult and pediatric patients suffering from RDEB, a severe skin disease caused by defects in the COL7A1 gene [3][4] - The therapy involves inserting the correct COL7A1 gene into a patient's skin cells ex vivo, leading to the production of functional type VII collagen [3] - Clinical results indicate that ZEVASKYN provides meaningful wound healing and pain reduction with a single application [3] Regulatory and Market Impact - The assignment of a unique J-code by CMS is expected to simplify claims and reimbursement processing, thereby supporting hospital adoption and patient access for ZEVASKYN [2] - J-codes are crucial for identifying non-orally administered medications in healthcare settings, streamlining medical billing and reimbursement processes [2]